Mineralys Therapeutics Inc expected to post a loss of 98 cents a share - Earnings Preview

Mineralys Therapeutics

09/05/2025 23:21

Mineralys Therapeutics Inc MLYS.OQ MLYS.O is expected to show no change in quarterly revenue when it reports  results on May 12 for the period ending March 31 2025

​LSEG's mean analyst estimate for Mineralys Therapeutics Inc is for a loss of 98 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Mineralys Therapeutics Inc is $42.00​, above​ its last closing price of $14.65. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-1.11
-1.08
-0.98
Beat
9
Sep. 30 2024
-0.87
-0.83
-1.13
Missed
-35.4
Jun. 30 2024
-0.70
-0.70
-0.83
Missed
-18.6​
Mar. 31 2024
-0.61
-0.67
-0.70
Missed
-4.8
​​Dec. 31 2023
-0.82
-0.61
Beat
26.1
Sep. 30 2023
-0.70
-0.76
-0.57
Beat
25​
Jun. 30 2023
-0.67
-0.72
-0.31
Beat
56.9
Mar. 31 2023
-0.88
-0.89
-0.51
Beat
42.7

This summary was machine generated May 9 at 22:21 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)